Monitor the 180-day compliance period for Nasdaq MVLS compliance by March 24, 2027; watch for shareholder approval vote on purchase warrants within 90 days of September 28, 2026; watch for any additional financing announcements given stated cash runway shortfall.
Price Chart
Executive Summary
Lantern Pharma is raising approximately $3.6 million in net proceeds through a registered direct offering of 1,469,725 shares of common stock at $1.09 per share and 2,200,000 pre-funded warrants, with a concurrent private placement of 3,669,725 purchase warrants exercisable at $1.09 per share subject to shareholder approval. The company disclosed it received a Nasdaq delisting notice on September 25, 2026 for failing to meet the $35 million market value of listed securities requirement, and stated that existing cash plus offering proceeds will not fund operations for 12 months, raising substantial doubt about its ability to continue as a going concern.
Key Facts
- Offering of 1,469,725 shares at $1.09/share and 2,200,000 pre-funded warrants at $1.0899/warrant for total gross proceeds of ~$4.0 million; net proceeds estimated at ~$3.6 million.
- Concurrent private placement of 3,669,725 purchase warrants at $1.09/share exercise price, exercisable upon shareholder approval; no public market for these warrants.
- Net tangible book deficit of $(3.22) million as of June 30, 2026; post-offering adjusted net tangible book value of $0.02/share; immediate dilution of $1.07/share dilution to new investors.
- Received Nasdaq delisting notice on September 25, 2026 for non-compliance with MVLS Requirement of $35 million; 180-day compliance period until March 24, 2027.
- Cash, cash equivalents and marketable securities of $7.36 million as of June 30, 2026; company states existing cash plus offering proceeds will not fund operations for 12 months.
- Auditor's report includes going concern explanatory paragraph; company expects to continue incurring losses and requires substantial additional funding.
- Placement agent: Rodman & Renshaw LLC; 7% cash fee on gross proceeds; 60-day company lock-up; 90-day officer/director lock-up.
- Placement agent warrants for 5% of shares sold at $1.3625/share exercise price.
Financial Impact
Net proceeds of ~$3.6 million from offering; immediate dilution of $1.07 per share to new investors; cash runway insufficient for 12 months; Nasdaq delisting risk if MVLS not regained by March 24, 2027.
Risk Factors
- Nasdaq delisting risk if market value of listed securities does not close at $35 million or more for 10 consecutive business days by March 24, 2027.
- Going concern risk: company states existing cash plus offering proceeds will not fund operations for 12 months; requires substantial additional funding.
- Immediate dilution of $1.07 per share to new investors; potential further dilution from exercise of outstanding options and warrants.
- No public market for pre-funded warrants or purchase warrants; limited liquidity for these instruments.
- Shareholder approval required for purchase warrants; no assurance of obtaining approval; warrants may be worthless if not approved.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-045049 |
| Document: 0001493152-26-045049-index-headers.html | 0001493152-26-045049 |
| Document: 0001493152-26-045049-index.html | 0001493152-26-045049 |
| Document: 0001493152-26-045049.txt | 0001493152-26-045049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers